Edition:
United States

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

57.17USD
20 Nov 2017
Change (% chg)

$-0.23 (-0.40%)
Prev Close
$57.40
Open
$57.17
Day's High
$57.17
Day's Low
$57.17
Volume
924
Avg. Vol
142,690
52-wk High
$97.14
52-wk Low
$45.05

Chart for

About

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $856.50
Shares Outstanding(Mil.): 14.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98

* Eagle Pharmaceuticals Inc reports third quarter 2017 results

Nov 08 2017

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

Oct 27 2017

UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

Oct 27 Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

Oct 27 2017

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

Oct 27 2017

BRIEF-EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY

* EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE

Oct 27 2017

BRIEF-Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl

* Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited

Sep 20 2017

BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

* EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

Sep 05 2017

BRIEF-Park West Asset Management reports 5.2 percent passive stake in Eagle Pharmaceuticals as on Aug 14, 2017

* Park West Asset Management LLC reports 5.2 percent passive stake in Eagle Pharmaceuticals Inc as on August 14, 2017 - SEC filing​ Source text : (http://bit.ly/2w8Kgk2) Further company coverage:

Aug 24 2017

BRIEF-Eagle Pharmaceuticals posts Q2 adj. earnings $0.49/shr

* Eagle Pharmaceuticals Inc reports second quarter 2017 results

Aug 09 2017

FDA rejects Eagle Pharmaceuticals' heat stroke treatment

Eagle Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex to treat heat stroke and requested an additional clinical trial, sending its shares down 20 percent.

Jul 26 2017

Earnings vs. Estimates